The use of medical hyperspectral technology to evaluate microcirculatory chaves in diabetic foot ulcers and to predict clinical outcomes

被引:145
作者
Khaodhiar, Lalita
Dinh, Thanh
Schomacker, Kevin T.
Panasyuk, Svetlana V.
Freeman, Jenny E.
Lew, Robert
Vo, Tiffany
Panasyuk, Alexander A.
Lima, Christina
Giurini, John M.
Lyons, Thomas E.
Veves, Aristidis
机构
[1] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Microcirculat Lab, Boston, MA 02215 USA
[2] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Joslin Beth Israel Deaconess Foot Ctr, Boston, MA 02215 USA
[3] HyperMed Inc, Waltham, MA USA
[4] Boston Univ, Dept Biostat, Boston, MA 02215 USA
关键词
D O I
10.2337/dc06-2209
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
OBJECTIVE - Foot ulceration is a serious complication of diabetes, and new techniques that can predict wound healing may prove very helpful. We tested the ability of medical hyperspectral technology (FIT), a novel diagnostic scanning technique that can quantify tissue oxy- and deoxyhemoglobin to predict diabetic foot ulcer healing. RESEARCH DESIGN AND METHODS - Ten type I diabetic patients with 21 foot ulcer sites, 13 type I diabetic patients without ulcers, and 14 nondiabetic control subjects were seen up to 4 times over a 6-month period. HT measurements of oxyhemoglobin (HT-oxy) and deoxyhemoglobin (HT-deoxy) were performed at or near the ulcer area and on the upper and lower extremity distant from the ulcer. An HT healing index for each site was calculated from the HT-oxy and -deoxy values. RESULTS - Hyperspectral tissue oxygenation measurements observed changes in tissue immediately surrounding the ulcer when comparing ulcers that heal and ulcers that do not heal (P < 0.001). The sensitivity, specificity, and positive and negative predictive values of the HT index for predicting healing were 93, 86, 93, and 86%, respectively, when evaluated on images taken at the first visit. Changes in HT-oxy among the three risk groups were noted for the metatarsal area of the foot (P < 0.05) and the palm(P < 0.01). Changes in HT-deoxy and the HT healing index were noted for the palm only (P < 0.05 and P < 0.01, respectively). CONCLUSIONS - FIT has the capability to identify microvascular abnormalities and tissue oxygenation in the diabetic foot and predict ulcer healing. FIT can assist in the management of foot ulceration.
引用
收藏
页码:903 / 910
页数:8
相关论文
共 17 条
[11]   Healing of diabetic neuropathic foot ulcers receiving standard treatment - A meta-analysis [J].
Margolis, DJ ;
Kantor, J ;
Berlin, JA .
DIABETES CARE, 1999, 22 (05) :692-695
[12]   Screening techniques to identify people at high risk for diabetic foot ulceration - A prospective multicenter trial [J].
Pham, H ;
Harkless, LB ;
Armstrong, DG ;
Giurini, JM ;
Harvey, C ;
Veves, A .
DIABETES CARE, 2000, 23 (05) :606-611
[13]   Incidence, outcomes, and cost of foot ulcers in patients with diabetes [J].
Ramsey, SD ;
Sandhu, N ;
Newton, K ;
Reiber, GE ;
Blough, D ;
Wagner, EH ;
McCullough, DK .
DIABETES CARE, 1999, 22 (03) :382-387
[14]   Percent change in wound area of diabetic foot ulcers over a 4-week period is a robust predictor of complete healing in a 12-week prospective trial [J].
Sheehan, P ;
Jones, P ;
Caselli, A ;
Giurini, JM ;
Veves, A .
DIABETES CARE, 2003, 26 (06) :1879-1882
[15]   Primary nociceptive afferents mediate the blood flow dysfunction in non-glabrous (hairy) skin of type 2 diabetes - A new model for the pathogenesis of microvascular dysfunction [J].
Stansberry, KB ;
Peppard, HR ;
Babyak, LM ;
Popp, G ;
McNitt, PM ;
Vinik, AI .
DIABETES CARE, 1999, 22 (09) :1549-1554
[16]   A randomized, controlled trial of promogran (a collagen/oxidized regenerated cellulose dressing) vs standard treatment in the management of diabetic foot ulcers [J].
Veves, A ;
Sheehan, P ;
Pham, HT .
ARCHIVES OF SURGERY, 2002, 137 (07) :822-827
[17]   Graftskin, a human skin equivalent, is effective in the management of noninfected neuropathic diabetic foot ulcers - A prospective randomized multicenter clinical trial [J].
Veves, A ;
Falanga, V ;
Armstrong, DG ;
Sabolinski, ML .
DIABETES CARE, 2001, 24 (02) :290-295